Is this you?
Request access for Bayview Research Group with your @partners.bayviewresearch.com work email. Intera will contact you to verify and set up your account — nothing auto-publishes.
Bayview Research Group
Unclaimed profileSite Network · Los Angeles, California (San Fernando Valley) · ~1 sites
Intera lens
ICP 4Lift (cardio sample) 0.24Recruit soph 0.43
Quality Scorecard (1–100)
Overall62Recruit68Ops65Sponsor55Ther56
Performance (observed)
Historical trials
99
Completed
65
Terminated/Withdrawn
15
Completion rate
81%
Active now
17
Phase 2
25
Phase 3
61
Realized enrollment
385,394
First study year
2002
Years active
24
Match confidence
high
Enrollment velocity (inf)
16,058
Therapeutic
Areas
Contraception, Diabetes, Dyslipidemia, Hypertension, Obesity, Alzheimer's, Vaccines, Musculoskeletal, Insomnia, 200+ Phase II-IV trials
Specialties
Contraception, diabetes, vaccines, menopausal, BPH, osteoarthritis, autoimmune, sleep, Alzheimer's, endometriosis
Breadth (conditions)
112
Languages
Y (multilingual staff)
States
California
Recruitment (web observed)
Meta Pixel
Yes
Facebook Ads
Yes
Trial Finder
Yes
Capability notes
Multilingual staff; relationships with medical clinics/physician networks; diverse recruitment; end-to-end site management
Relationships
Sponsors
Pfizer; Novo Nordisk A/S; BioNTech SE; AbbVie; Eli Lilly and Company; Astellas Pharma Global Development, Inc.
CROs
IQVIA Pty Ltd; Syneos Health; Teva Branded Pharmaceutical Products R&D, Inc.
Partnerships
Sponsor-CRO partnerships
Owner / parent
Unknown
Expansion
Valley Village (San Fernando Valley), CA
Recent hiring
Y (Clinical Research Assistant)
Capacity & people
Investigators
—
Coordinators
—
CEO
Michael Feist (CEO/Manager)
VP Clinical Ops
Karen Hung (long-time research site manager)
VP Site Ops
Unknown
VP Recruitment
Unknown
Emails
Michael Feist (800-831-8308 ext. 333), Karen Hung (ext. 123)
Tech & DCT
eSource
Yes
Builds tech
Vendors
Tech stack
e-CRF mentioned; no specific CTMS named
Recruiting visible
N
Notes
Weak Intera fit: Single site (Los Angeles only); small footprint; 200+ trials over 12 years is steady but not high-volume growth signal; no advertised patient recruitment services; no modern tech stack visible. Established, reliable but too geographically limited and small-scale for Intera's network model.
Recommendation features (sample indication)
Ind fit 0.42Liftability 0.24Overall62
FUTURE MOAT: absolute enrollment rates, funnel CPR, measured SSU, screen-fail reasons.